Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 14/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | YES1 | P07947 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864051 | 0.92 | ABL1 (0.40) | NMT1ABL1YES1SRCKDR | |
| SCHEMBL5864868 | 0.89 | SIGMAR1 (0.38) | NMT1ABL1YES1SRCKDR | |
| SCHEMBL5864216 | 0.86 | SIGMAR1 (0.40) | NMT1NR1H2NR1H3ALDH1A1KEAP1 | |
| SCHEMBL5863878 | 0.85 | OPRM1 (0.39) | NMT1ALDH1A1KEAP1 | |
| SCHEMBL5864026 | 0.84 | KEAP1 (0.39) | NR1H2NR1H3KEAP1NFE2L2 | |
| SCHEMBL5864171 | 0.82 | HRH3 (0.37) | ALDH1A1 | |
| SCHEMBL5864175 | 0.81 | KEAP1 (0.40) | NR1H2NR1H3ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL5863949 | 0.81 | KEAP1 (0.40) | NR1H2NR1H3ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL5863899 | 0.80 | DRD2 (0.38) | NMT1KEAP1NFE2L2 | |
| SCHEMBL5863904 | 0.80 | DRD2 (0.38) | NMT1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | NMT1 3050/4885ABL1 1155/4885YES1 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.